Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Genomic Valley Biotech Ltd - 539206 - Closure of Trading Window

 The Company hereby informs the stock exchange that the meeting of the Board of Directors held today is adjourned and will continue of Sunday, 29th May, 2022 at 04.00 p.m. to consider the remaining agenda including consideration and approval of financial results for the aforesaid period. The financial results shall be released to the exchanges as soon as approved by the Board. Pursuant to the Code of Conduct for Prevention of Insider Trading of the Company under SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, we would like to inform you that the trading window for the purpose of trading in the securities of the Company by its Designated persons has been closed from 01st April, 2022 till 48 hours of declaration of results i.e. 31st May, 2022 (both days inclusive).
28-05-2022
Bigul

Genomic Valley Biotech Ltd - 539206 - Intimation Regarding Adjournment Of Board Meeting To Consider Audited Financial Results For The Quarter And Year Ended March 31, 2022

 This is with reference to our earlier announcement dated 20th May, 2022 regarding intimation of the Meeting of the Board of Directors of the Company scheduled to be held on Saturday, 28th May, 2022, inter-alia, to consider and approve Audited Financial Results for the quarter and year ended 31st March, 2022. We now wish to inform that the Chairman with the consent of all the directors present at the meeting today has decided to adjourn the meeting to Sunday, 29th May, 2022 at 04.00 p.m. to consider and approve the financial results of the Company for the quarter and financial year ended on 31st March, 2022. Therefore, the Company hereby informs the stock exchange that the meeting of the Board of Directors held today is adjourned and will continue of Sunday, 29th May, 2022 at 04.00 p.m. to consider the remaining agenda including consideration and approval of financial results for the aforesaid period.
28-05-2022
Bigul

Genomic Valley Biotech Ltd - 539206 - Announcement under Regulation 30 (LODR)-Meeting Updates

 Intimation regarding Adjournment of Board Meeting to consider Audited Financial Results for the quarter and year ended March 31, 2022
28-05-2022
Bigul

Genomic Valley Biotech Ltd - 539206 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Please find enclosed herewith the Newspaper Advertisements published for the Notice of Board Meeting to be held on 28th May, 2022, inter-alia, to consider and approve the Audited Financial Results for the quarter and year ended 31st March, 2022, in the newspapers, Financial Express (English Edition) and Jansatta (Hindi Edition) on 21st May, 2022.
21-05-2022
Bigul

Genomic Valley Biotech Ltd - 539206 - Closure of Trading Window

 In pursuant of Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Notice is hereby given that a Meeting of the Board of Directors of the Company is scheduled to be held on Saturday, the 28th May, 2022 at 11:45 A.M. inter-alia, to consider and approve the Audited Financial Results for the quarter and year ended 31st March, 2022. Pursuant to the Code of Conduct for Prevention of Insider Trading of the Company under SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, we would like to inform you that the trading window for the purpose of trading in the securities of the Company by its Designated persons has been closed from 01st April, 2022 till 48 hours of declaration of results i.e. 30th May, 2022 (both days inclusive).
20-05-2022
Bigul

Genomic Valley Biotech Ltd - 539206 - Board Meeting Intimation for Considering Audited Financial Results For The Quarter And Year Ended March 31, 2022

 Genomic Valley Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2022 ,inter alia, to consider and approve Audited Financial Results for the quarter and year ended March 31, 2022
20-05-2022
Bigul

Genomic Valley Biotech Ltd - 539206 - Intimation Regarding The Applicability Of SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144

 This is to confirm you that Genomic Valley Biotech Limited ('Company') do not fall under the ambit of 'Large Entities' as per the SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 regarding the Fund raising of Debt Securities by Large Entities and do not have an outstanding long term borrowing of Rs. 100 crores or above with original maturity of more than one (1) year.
13-05-2022
Bigul

Genomic Valley Biotech Ltd - 539206 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2

 Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company Genomic Valley Biotech Ltd 2 CIN NO. L01122HR1994PLC033029 3 Report filed for FY 2021-2022 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* FY 2021-22, 2022-23 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) Nil 8Quantum of (d), which has been met from (c)(e)* Not Applicable 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* Not Applicable Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)FY 2020-21, 2021-22 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-Hanuman PrasadDesignation :-Company Secretary Name of the Chief Financial Officer :- Lalit Shah Designation : -Chief Financial Officer Date: 13/05/2022
13-05-2022
Bigul

Genomic Valley Biotech Ltd - 539206 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate

 Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayGenomic Valley Biotech Ltd 2CINL01122HR1994PLC033029 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Hanuman Prasad Designation: Company Secretary EmailId: genomicvalley@gmail.com Name of the Chief Financial Officer: Lalit Shah Designation: Chief Financial Officer EmailId: genomicvalley@gmail.com Date: 26/04/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
26-04-2022
Bigul

Genomic Valley Biotech Ltd - 539206 - Intimation Regarding The Applicability Of SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144

 This is to confirm you that Genomic Valley Biotech Limited ('Company') do not fall under the ambit of 'Large Entities' as per the SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 regarding the Fund raising of Debt Securities by Large Entities and do not have an outstanding long term borrowing of Rs. 100 crores or above with original maturity of more than one (1) year.
26-04-2022
Next Page
Close

Let's Open Free Demat Account